

Embargoed: 0700hrs, 10 February 2011

Akers Biosciences, Inc

("ABI" or "the Company")

Issue of Equity

Directors' Holdings

The Board of Akers Biosciences, Inc (AIM: AKR) today announces that the warrants announced on 1 February 2011 have all been exercised, in respect of which the Company has issued and allotted 4,000,000 common shares of no par value ("Warrant Shares"). The exercise of the warrants has raised a further £160,000 in addition to the £2,000,000, before expenses, raised in the placing announced last week.

Application was made for the Warrant Shares to be admitted to trading on AIM, together with the 50,000,000 Placing Shares, and dealings in the Warrant Shares and Placing Shares will commence at 8.00am today, 10 February 2011.

The Warrant Shares and the Placing Shares will rank pari passu with the existing shares of the Company and, following admission, the total issued share capital of the Company will comprise 168,715,666 common shares of no par value.

Following the issue of the Warrants Shares, the holdings of the directors of ABI are as follows:

Name	Number of Warrant Shares issued	Total common shares held	Percentage of issued share capital	Outstanding options and warrants
Raymond F. Akers	921,636	8,824,338	5.2%	6,550,000
Thomas A. Nicolette	1,456,364	6,000,000	3.6%	5,050,000
Edward A. Mulhare	650,000	2,256,863	1.3%	1,844,000

Enquiries:

Akers Biosciences
Thomas A. Nicolette, President and Chief Executive Officer

Tel: + 1 856 848 8698

Daniel Stewart & Company plc (Nomad and Broker)
Antony Legge/Emma Earl

Tel: + 44 (0) 20 7776 6550

M: Communications
Ben Simons

Tel: + 44 (0) 20 7920 2340

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the

consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com